Michael C Flint

US Patent:

8557548, Oct 15, 2013

Filed:

Mar 22, 2013

Appl. No.:

13/848909

Inventors:

Robert G. K. Donald - South Orange NJ, US
Kathrin Ute Jansen - Allendale NJ, US
Michael James Flint - Decatur GA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

C12N 15/70
C12P 21/06

US Classification:

435 713, 435 691, 435 711, 43525233, 536 237

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20070224167, Sep 27, 2007

Filed:

Feb 9, 2007

Appl. No.:

11/704505

Inventors:

Emillo Emini - Dresher PA, US
Michael Flint - Wayne PA, US
Anita Howe - Paoli PA, US
Bruce Malcolm - Paoli PA, US
Stanley Mullen - Lincoln Park NJ, US
Robert Ralston - Union NJ, US
Xiao Tong - East Brunswick NJ, US

Assignee:

Schering Corporation - Kenilworth NJ
ViroPharma Incorporated - Exton PA
Wyeth - Madison NJ

International Classification:

A61K 38/21
A61K 31/7056
A61K 31/407
A61K 31/343

US Classification:

424085400, 514412000, 514043000, 514469000

Abstract:

Novel hepatitis C virus (“HCV”) inhibitor combinations comprising an HCV protease inhibitor and HCV polymerase inhibitor, and optionally one or more biologically active agents, as well as uses of these combinations as HCV inhibitors and for treating hepatitis C and related disorders are disclosed.

US Patent:

20210024903, Jan 28, 2021

Filed:

Jul 7, 2020

Appl. No.:

16/922952

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G. K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Kathrin Ute Jansen - New York NY, US
Maninder K. Sidhu - New City NY, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Garnerville NY, US
Weiqiang Sun - Morristown NJ, US

International Classification:

C12N 9/10
C07K 14/33
C12N 1/20

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing and in producing toxins.

US Patent:

20200254081, Aug 13, 2020

Filed:

Sep 14, 2018

Appl. No.:

16/647124

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Nicholas Randolph Everard Kitchin - Sandwich, GB
Justin Keith Moran - West Nyack NY, US
Louise Pedneault - New York NY, US
Michael W. Pride - Staten Island NY, US
Mark Edward Ruppen - Cresco PA, US
Christopher Frederick Webber - Sandwich, GB

International Classification:

A61K 39/08
A61K 9/19

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a toxoid A and/or a toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a infection. The method includes administering to the human an effective dose of a composition, which includes a toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against toxin A and/or toxin B is sustained.

US Patent:

20200165582, May 28, 2020

Filed:

Dec 5, 2019

Appl. No.:

16/704744

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Kathrin Ute Jansen - New York NY, US
Maninder K. Sidhu - Bangor PA, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Cresco PA, US
Weiqiang Sun - Morristown NJ, US

International Classification:

C12N 9/10
C12N 1/20
C07K 14/33

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing and in producing toxins.

US Patent:

20200095290, Mar 26, 2020

Filed:

Dec 5, 2019

Appl. No.:

16/704777

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Maninder K. Sidhu - Bangor PA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Cresco PA, US
Michael James Flint - Decatur GA, US

International Classification:

C07K 14/33
C07K 16/12
C12N 15/74
C12N 9/10
C12N 9/99
A61K 39/08

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20190202873, Jul 4, 2019

Filed:

Mar 20, 2019

Appl. No.:

16/359267

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Maninder K. Sidhu - New City NY, US
Narender Kumar Kalyan - Ridgewood NJ, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Garnerville NY, US
Michael James Flint - Decatur GA, US

International Classification:

C07K 14/33
A61K 39/08
C12N 9/99
C12N 9/10
C07K 16/12
C12N 15/74

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20190112584, Apr 18, 2019

Filed:

Aug 19, 2018

Appl. No.:

16/104938

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G. K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Kathrin Ute Jansen - New York NY, US
Maninder K. Sidhu - New City NY, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Garnerville NY, US
Weiqiang Sun - Morristown NJ, US

International Classification:

C12N 9/10
C07K 14/33
C12N 1/20

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing and in producing toxins.